Long-term Safety and Efficacy of Adipose-derived Stem Cells to Treat Complex Perianal Fistulas in Patients Participating in the FATT-1 Randomized Controlled Trial

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this extension is to investigate and confirm the long-term (6 months) safety and efficacy of the preceding FATT-1 trial [ClinicalTrials.gov identifier: NTC00475410], which studied patients with perianal fistula treated having received adipose-derived adult stem cell (ASC)and/or fibrin glue.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cellerix; Tigenix S.A.U.
• Treatments: Fibrin Tissue Adhesive

Criteria

Inclusion Criteria:

• At least 1 dose of the treatment assigned in the FATT-1 trial

• Informed consent

Exclusion Criteria:

• Other experimental drugs other than Cx401 during the follow-up period